Helus Pharma, the commercial operating name of Cybin Inc. (Nasdaq: HELP; Cboe Canada: HELP), said on July 21, 2026, that it had completed enrolment ahead of schedule in the Phase 3 APPROACH study of HLP003 as an adjunctive treatment for major depressive disorder. The 223-participant pivotal trial remains on track for a topline data readout in the fourth quarter of 2026, according to the company.
The enrolment milestone moves Helus Pharma from patient recruitment into the more consequential period of completing follow-up, cleaning and locking the clinical database, and analysing the prespecified endpoints. It does not provide new evidence that HLP003 is effective or sufficiently safe, but it reduces one important source of operational uncertainty around the company’s lead programme.
That distinction matters because HLP003 is entering a far more demanding evidentiary test than the small Phase 1/2a study that generated its attention-grabbing durability and remission data. APPROACH is designed to determine whether two doses of the investigational deuterated psilocin analogue can produce a statistically persuasive and clinically relevant benefit over placebo in adults whose depression remains inadequately controlled despite stable antidepressant therapy.
What does early completion of APPROACH enrolment change for HLP003’s Phase 3 risk profile?
APPROACH enrolled 223 adults with moderate to severe major depressive disorder, slightly above the original target of approximately 220 participants. Eligible participants were required to have a Montgomery-Asberg Depression Rating Scale score of at least 24 and an inadequate response while taking a stable antidepressant dose.
Participants were randomised equally to receive either 16 milligrams of HLP003 or placebo. Both groups follow a two-dose schedule, with the administrations separated by three weeks. The primary endpoint measures the change from baseline in depression severity at six weeks after the first dose, while the key secondary endpoint examines the change at 12 weeks.
Completing enrolment ahead of schedule suggests that Helus Pharma and its clinical partners were able to identify eligible participants and activate suitable study sites without a material recruitment delay. This is meaningful in psychiatric drug development, where strict eligibility criteria, competing studies, site capacity and participant retention can disrupt timelines.
Management also said the enrolled population had baseline disease severity comparable with the earlier study. That may support continuity between development phases, although baseline similarity alone cannot establish that the Phase 3 population will reproduce the earlier treatment response.
The immediate operational risk now shifts from recruitment to data integrity and follow-up. Participant retention, adherence to the dosing and monitoring protocol, missing data, endpoint completion and consistency across research sites will influence the interpretability of the results. Early enrolment completion is therefore a credible execution milestone, but it does not reduce the biological uncertainty surrounding HLP003.
Can APPROACH overcome the blinding and placebo-response problems facing psychedelic trials?
Randomised, double-blind, placebo-controlled trials of psychedelic or perception-altering medicines face an unusual challenge. Participants and clinical staff may infer whether an active treatment was administered because of its acute subjective effects, creating what is commonly described as functional unblinding.
If participants believe they received the active drug, expectations may influence symptom reporting. Investigators who become aware of the dosing experience may also introduce unintended bias into assessments. Major depressive disorder trials already face variable placebo responses, making protection of the blind particularly important.
Helus Pharma has sought to address this problem through remote, independent and blinded outcome raters who do not receive information about the participant’s dosing experience. The broader PARADIGM programme also uses procedures intended to separate observations made during administration from the teams responsible for evaluating depression outcomes.
These measures strengthen the design, but they cannot make the challenge disappear. The fourth-quarter readout will need to show that the treatment effect is sufficiently large and consistent to remain persuasive despite the possibility that some participants correctly guessed their assignment.
The six-week primary endpoint provides the first pivotal test, while the 12-week endpoint will help establish whether any benefit persists beyond the immediate post-dosing period. A statistically positive six-week result accompanied by weakening separation at 12 weeks would create a different clinical and commercial profile from a response that remains stable across both time points.
How much confidence should investors place in HLP003’s striking Phase 2 results?
Helus Pharma has repeatedly highlighted company-reported Phase 2 findings showing a mean reduction of approximately 23 points in Montgomery-Asberg Depression Rating Scale scores at 12 months among participants who received two 16-milligram doses. The company also reported a 100% response rate and a 71% remission rate using a remission threshold of 10 or below.
Those figures provide a strong rationale for conducting Phase 3 development, but the size and structure of the supporting dataset require careful interpretation. Only seven participants who received two 16-milligram doses were included in the reported 12-month analysis. The long-term result was measured against baseline rather than against a continuing placebo group, making it unsuitable as confirmatory evidence of efficacy.
The company has also said that all seven participants would have met remission criteria using a threshold of 12 or below, a cutoff used in some peer studies. Changing a threshold can alter how participants are classified, but it does not change their underlying symptom scores. The pivotal analysis will therefore carry far greater weight than debates about which remission definition presents the earlier dataset most favourably.
The Phase 1/2a programme was primarily designed to examine safety, tolerability, pharmacokinetics and pharmacodynamic effects, with depression outcomes included as secondary evidence. Its encouraging efficacy signal supported the United States Food and Drug Administration’s Breakthrough Therapy designation and the decision to proceed into Phase 3, but it was not designed to provide the level of evidence expected from an adequate and well-controlled pivotal trial.
APPROACH offers a substantially larger sample, a contemporaneous placebo group and prespecified six-week and 12-week comparisons. The critical questions will be the size of the placebo-adjusted improvement, the consistency of the response, the proportion of participants achieving response or remission, and whether the safety profile remains manageable across the broader population.
Why could HLP003’s adjunctive two-dose model matter without guaranteeing clinical adoption?
HLP003 is being developed as an adjunctive therapy, meaning participants remain on their existing antidepressant while receiving the investigational treatment. This approach could avoid the medication tapering and withdrawal concerns that can complicate studies requiring patients to discontinue background therapy.
An adjunctive indication could also position HLP003 for patients who have experienced an inadequate response before they meet stricter definitions of treatment-resistant depression. That potentially broadens the clinically relevant population, although the eventual label would depend on the evidence submitted and any approval decision by the United States Food and Drug Administration.
The intermittent two-dose model is commercially attractive because it contrasts with daily oral medication and potentially repeated maintenance treatment. If durable benefit is confirmed, fewer administration sessions could reduce some of the burden on patients and clinics.
However, administration frequency is only one part of the adoption equation. A serotonergic psychedelic treatment may require supervised dosing, trained personnel, dedicated clinical space, monitoring protocols and sufficient time to manage acute subjective effects. Those requirements could limit throughput even if dosing occurs only occasionally.
Johnson & Johnson’s expanding Spravato business demonstrates that clinic-administered depression treatment can achieve meaningful commercial scale. It does not validate HLP003, which has a different mechanism, dosing model, clinical programme and potential target population. Its relevance is primarily operational, showing that reimbursement systems and specialist treatment networks can develop around an interventional psychiatry product when the evidence, label and economics are supportive.
How does the United States Food and Drug Administration’s final guidance raise the bar?
The United States Food and Drug Administration finalised its guidance for clinical investigations involving psychedelic drugs in July 2026. The document emphasises adequate and well-controlled trials, interpretable study designs, comprehensive safety monitoring, appropriate management of acute effects and sufficient chemistry, manufacturing and controls information.
Helus Pharma said the PARADIGM programme incorporates considerations contained in the guidance, including placebo-controlled evaluation, blinded outcome assessment, safety monitoring and longer-term collection of durability and redosing data. That design work is important, but the company’s assessment of alignment should not be confused with a regulatory endorsement of the programme or its eventual results.
HLP003’s Breakthrough Therapy designation provides opportunities for closer communication with the agency and potentially more efficient development and review. It is not an approval, does not confirm clinical efficacy and does not guarantee that an application will receive Priority Review or a favourable decision.
Management has identified 2028 as a potential target for a New Drug Application. Reaching that point will depend on more than a positive APPROACH result. Helus Pharma will need supportive evidence from the second pivotal EMBRACE study, longer-term safety and redosing information from EXTEND, a suitable manufacturing package, and agreement with regulators on how the totality of the data supports the proposed indication and treatment framework.
Is Helus Pharma financially equipped to complete its late-stage HLP003 programme?
Helus Pharma reported US$157.3 million in cash as of March 31, 2026, before completing a US$50 million underwritten offering in June. The financing involved the issue of approximately 10.3 million shares at US$4.85 each and was intended to support HLP003, HLP004, HLP005 and general corporate requirements.
The stronger balance sheet gives the company additional capacity to advance APPROACH, EMBRACE and EXTEND. It does not remove financing risk. Helus Pharma used US$133.3 million in operating activities during fiscal 2026, while its annual net loss widened to US$148 million as clinical development expenditure increased.
That spending trajectory reflects the cost of running multiple late-stage psychiatric studies and building the supporting regulatory, medical and manufacturing functions. Future expenditure could remain elevated as EMBRACE enrolment progresses and preparations for a potential marketing application become more demanding.
Investor sentiment turned constructive following the enrolment announcement. Helus Pharma shares closed July 21 at US$8.10, up approximately 13.9% for the session. The stock was about 21% higher than its July 14 close and approximately 20% above its June 22 close, while remaining below its 52-week high of US$9.12.
The reaction shows that investors view completion of enrolment and the approaching fourth-quarter readout as meaningful catalysts. It also reinforces the binary nature of the valuation. A pivotal-stage biotechnology company without commercial revenue can experience sharp changes in market value when a large part of its investment case rests on one lead clinical programme.
Which results will determine whether early enrolment becomes a viable depression medicine?
The fourth-quarter APPROACH readout will need to provide more than a positive headline. The placebo-adjusted change in Montgomery-Asberg Depression Rating Scale score at six weeks will be the central result, but the 12-week outcome, response and remission rates, treatment discontinuations, serious adverse events, suicidality assessments and consistency across study sites will determine how regulators and clinicians interpret the programme.
EMBRACE will then become essential to replication and dose selection. That study is designed to enrol approximately 330 participants and compare 16-milligram and 8-milligram HLP003 regimens with placebo. A coherent dose-response pattern and a second persuasive efficacy result would materially strengthen the regulatory package.
EXTEND will address another question that APPROACH cannot settle on its own: what happens when participants relapse or fail to respond. Its longer-term safety, durability and redosing evidence will help define whether HLP003 could support a manageable treatment pathway rather than a one-time experimental intervention.
Helus Pharma has completed the recruitment task sooner than expected. The programme’s value will now be determined by whether the blinded data confirm a meaningful treatment effect, whether the result can be replicated, and whether an intermittent psychedelic therapy can be delivered safely and economically within routine psychiatric care.
